Related articles:

Ophthotech Corporation: Ophthotech Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
February 28, 2017

Ophthotech Corporation: Ophthotech Corporation to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on Tuesday, February 28, 2017
February 22, 2017

Ophthotech Corporation: Ophthotech Corporation to Report Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 8, 2016
October 24, 2016

Ophthotech Corporation: Ophthotech Reports Second Quarter 2016 Financial and Operating Results
August 03, 2016

Ophthotech Corporation: Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016
July 25, 2016

Ophthotech Corporation: Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration
June 20, 2016

Ophthotech Corporation: Ophthotech Reports First Quarter 2016 Financial and Operating Results
May 04, 2016

Ophthotech Corporation: Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
April 26, 2016

Ophthotech Corporation: Ophthotech Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
February 24, 2016

Ophthotech Corporation: Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors
January 06, 2016

Ophthotech Corporation: Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
January 05, 2016

Ophthotech Corporation: Ophthotech Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 04, 2016

Ophthotech Corporation: Ophthotech Announces that Genentech, a Roche Wholly-Owned Subsidiary, Elects to Exercise Its Right to Opt-in to the Novartis Portion of the Ophthotech / Novartis Ex-US Agreement for Fovista® to Treat Wet Age-Related Macular Degeneration
November 17, 2015

Ophthotech Corporation: Ophthotech Reports Third Quarter 2015 Financial and Operating Results
November 05, 2015

Ophthotech Corporation: Ophthotech Corporation to Report Third Quarter 2015 Financial Results and Host Conference Call on Thursday, November 5, 2015
November 02, 2015

Ophthotech Corporation: Ophthotech Completes Patient Recruitment of the Second Phase 3 Pivotal Trial of Fovista® Anti-PDGF Therapy in Combination with Lucentis® in Wet Age-Related Macular Degeneration
October 26, 2015

Ophthotech Corporation: Ophthotech Reports Second Quarter 2015 Financial and Operating Results
August 05, 2015

Ophthotech Corporation: Ophthotech Corporation to Report Second Quarter 2015 Financial Results and Host Conference Call on Wednesday, August 5, 2015
July 29, 2015

Ophthotech Corporation: Ophthotech Announces New Senior Leadership Appointments
July 21, 2015

Ophthotech Corporation: Ophthotech Reports First Quarter 2015 Financial and Operating Results
May 11, 2015

Ophthotech Corporation: Ophthotech Corporation to Announce First Quarter 2015 Financial Results and Host Conference Call on Monday, May 11, 2015
May 05, 2015

Ophthotech Corporation: Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®
March 10, 2015

Ophthotech Corporation: Ophthotech Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
February 23, 2015

Ophthotech Corporation: Ophthotech Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, February 23, 2015
February 18, 2015

Ophthotech Corporation: Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results
November 11, 2014

Ophthotech Corporation: Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
November 03, 2014

Ophthotech Corporation: Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
September 23, 2014

Ophthotech Corporation: Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®
September 08, 2014

Ophthotech Corporation: Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update
August 06, 2014

Ophthotech Corporation: Ophthotech Corporation to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
July 29, 2014

Ophthotech Corporation: Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis
May 19, 2014

Ophthotech Corporation: Ophthotech Reports First Quarter 2014 Financial Results and Provides Business Update
May 13, 2014

Ophthotech Corporation: Ophthotech Corporation to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
May 08, 2014

Ophthotech Corporation: Ophthotech Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
February 27, 2014

Ophthotech Corporation: Ophthotech Corporation to Announce Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
February 24, 2014

Ophthotech Corporation: Ophthotech Corporation Announces Closing of Registered Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 18, 2014

Ophthotech Corporation: Ophthotech Corporation Announces Pricing of Public Offering of Common Stock
February 11, 2014

Ophthotech Corporation: Ophthotech Corporation Announces Proposed Public Offering of Common Stock
February 10, 2014

Ophthotech Corporation: Ophthotech Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update
November 13, 2013